OpenEvidence founder: Medical AI shows that our nation's investment is paying dividends

Company Overview - Open Evidence is an AI co-pilot for physicians designed to increase accuracy for patient care [1][2] - The company has a $6 billion valuation [1] - Google is one of Open Evidence's largest investors [9][10] Product & Technology - Open Evidence is a free AI chatbot for healthcare providers, similar to ChatGPT, assisting doctors in making clinical decisions [1][2] - The AI is trained on peer-reviewed medical journals from sources like the New England Journal of Medicine, the American Medical Association, NCCN, and the ACC [13] - The company emphasizes that doctors are always the "last mile," making the final decisions, similar to the philosophy behind the Bloomberg terminal [5][6] Market Impact & Usage - Open Evidence claims that about 40% of doctors in the US are already using the chatbot [1] - More than 100 million Americans will be treated by a doctor using Open Evidence this year [3] - In October alone, there were 17 million AI clinical consultations from logged-in, verified US doctors and other healthcare professionals [3] Competitive Advantage - Open Evidence focuses specifically on providing accurate medical answers to physicians at the point of care, unlike larger AI labs that build AI horizontally [11][12] - Strategic partnerships with leading medical societies and training on gold standard medical knowledge provide a competitive moat [13][14] Industry Trends & Challenges - The US government is projecting a shortage of 100,000 doctors by the end of the decade [7] - Doctors are facing burnout due to excessive medical information and patient loads, creating a need for force multipliers like AI [7][8]